Targeted Radiopharma US 2026

Almac Sciences are delighted to be attending the 5th Targeted Radiopharmaceuticals Summit USA from the 21st – 23rd July, in San Diego, CA.

Alastair Hay, Vice President of Peptides at Almac Sciences, will be attending and contributing to discussions shaping the future of targeted radiopharmaceuticals. This presents a valuable opportunity to collaborate, share insight, and drive innovation within this rapidly evolving field.

About the 2026 Targeted Radiopharmaceuticals Summit USA

The 5th Targeted Radiopharmaceuticals Summit USA brings together leading experts across discovery, clinical development, and manufacturing to accelerate the next generation of precision oncology therapies.

With 200+ attendees and 60+ speakers, the event offers a comprehensive platform to explore cutting‑edge advances in radioligand therapy while building valuable industry connections.

To find out more information and to register for the event, please visit the Targeted Radiopharma US website.